SAIL Fusion Announces the U.S. Commercial Launch of its BowTie™ Sacroiliac Fusion System
Pierce Nunley, MD conducted the first BowTie surgery as part of a limited market release
DEL MAR, Calif., June 12, 2024–(BUSINESS WIRE)–SAIL Fusion, a medical device company focused on advancing the surgical treatment of sacroiliac joint dysfunction through solutions built upon proven AO principles, today announced the U.S. commercial launch of its novel BowTie Sacroiliac Fusion System. BowTie is the first SI fusion technology to be based on long-standing, validated joint fusion principles established by the AO foundation and is now the lone commercially available device that integrates both intra‑articular and transfixing components. Pierce Nunley, MD, Director of the Spine Institute of Louisiana, performed the first domestic surgery on June 11th at The Spine Center of Excellence in Shreveport, Louisiana.
The MIS BowTie technology and its posterior-inferior surgical technique achieve the AO-based principles of minimal tissue disruption, thorough joint preparation, and rigid fixation to enable true and robust arthrodesis. The device features a novel bowtie shape as well as integrated transfixation and iliac screws to maximize rigidity. It also utilizes a proprietary porous structure and roughened surface technology to facilitate osteointegration.
Today’s first domestic surgery is part of a limited commercial release that will be expanded in the coming months.
Dr. Nunley commented, “As a spine surgeon, our focus is all about how to create a proper fusion with proper biomechanics. Unlike other devices, BowTie is doing everything we know about fusing joints. It directly addresses the joint decortication of the sacrum and ilium with good bleeding bone for early osseointegration. Then placing a device that really has three biomechanical fixations: one is the BowTie that creates an interlocking fixation, two is the iliac screw, and three is the transfixation screw that crosses the ilium and into the sacrum. This is the best combination to ensure an extremely high fusion rate. There’s nothing else like it.”
“We are extremely excited to begin our limited commercial release of BowTie here in the United States,” remarked David Jansen, the President & CEO of SAIL. “This is an important milestone in recognizing surgeons’ desire to bring AO principles to SI fusion procedures. Dr. Nunley’s procedure today is the first major step in disrupting an SI fusion industry that has been far too reliant on lateral devices that are more appropriate for stabilization than true joint fusion.”
About SAIL Fusion
SAIL Fusion is a medical device company advancing the treatment of sacroiliac joint dysfunction. The company is focused on providing lasting relief for patients with chronic pain caused by the pelvis and is the first to apply proven joint fusion principles established by the AO foundation to the SI joint. SAIL’s proprietary BowTie technology and posterior-inferior surgical technique minimize tissue disruption, thoroughly prepare the joint, and provide rigid fixation to enable true and robust SI joint fusion. To learn more, visit www.SAILspine.com.
SAIL Fusion is a Cor Medical Ventures portfolio company, co-founded with orthopedic surgeons Dr. Hyun Bae, Dr. Vikas Patel, and Dr. Peter Whang.
Contacts
Andrew Shepherd
SAIL Fusion
Media@SAILspine.com
